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EDITORIAL
Visceral  adipose  tissue: A clue  to the obesity-asthmar
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tendency  for  higher  waist  circumference  (cm),  than  womenendotype(s)?
Obesity  and  asthma  are  both  prevalent  chronic  pathologi-
cal  conditions  throughout  the  world,  representing  today  a
serious  global  economic  and  social  burden  to  health  care
systems  and  patient’s  quality  of  life.1,2 Overweight  and  obe-
sity  are  deﬁned  as  abnormal  or  excessive  fat  accumulation
that  presents  a  risk  to  health.  The  worldwide  prevalence
of  obesity  more  than  doubled  between  1980  and  in  2014,
when  more  than  1.9  billion  adults  were  overweight  and  over
600  million  of  these  were  obese.  Overall,  about  39%  of  the
world’s  adult  population  (40%  of  women  and  38%  of  men)  are
overweight,  and  13%  are  obese  (15%  of  women  and  11%  of
men).3
The  National  Health  and  Nutrition  Examination  Survey
(NHANES)  data  has  indicated  that  in  the  USA  almost  one  in
three  asthma  patients  are  obese  and  that  the  prevalence  of
obesity  between  subjects  with  current  asthma  has  increased
in  a  23  years  span  from  21.3%  (NHANES  I)  to  32.8%  (NHANES
III).4 A  recent  meta-analysis  showed  that  weight  gain  per
se,  almost  doubled  the  odds  of  incident  asthma.5 Studying
a  representative  sample  of  32,644  adults  (52.6%  females)
from  the  4th  Portuguese  National  Health  Survey,  we  also
recently  found  that  obesity  more  than  quadrupled  the  odds
of  incident  asthma,  increasing  also  the  odds  of  a  more  per-
sistent  and  severe  asthma  phenotype.6 On  the  other  hand,
in  the  same  meta-analysis,  weight  loss  was  associated  with
signiﬁcant  improvements  in  mean  scores  for  symptoms,  res-
cue  medication,  and  asthma  exacerbations,  in  an  included
randomized  controlled  trial.5 Additional  evidence,  gathered
from  observational  studies,  also  showed  improvements  in
asthma  control-related  outcomes  with  weight  loss.
Asthma  is  nowadays  seen  not  as  a  single  disease  entity  but
a  syndrome  that  associates  characteristic  recurrent  symp-
toms,  variable  airﬂow  obstruction  and  underlying  airways
inﬂammation.  It  is  now  recognized  that  asthma  encom-
pass  different  driving  biomechanical  and  cellular  pathways
that  translate  into  different  clinical  expressions  (e.g.  phen-
otypes)  but  also  different  pathophysiological  mechanisms
(e.g.  endotypes)  and,  for  some  of  those,  unfavourable
response  to  standard,  guideline-oriented,  pharmacological
treatments.7 In  fact,  obesity  can  negatively  inﬂuence  the
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r  obese  adults  with  severe  asthma  exacerbations  have
onger  durations  of  treatment  in  the  emergency  room  (and
lso  more  in-hospital  admissions),  and  increasing  body  mass
ndex  (BMI)  has  been  associated  with  decreased  response  to
nhaled  corticosteroid,  but  not  leukotriene-antagonist.5
Obesity-related/associated  asthma  is  more  and  more
een  at  our  clinics,  especially  in  women,  and  as  one
f  the  exacerbation-prone  asthma  phenotypes.6,7 There-
ore,  identiﬁed  the  underling  mechanisms  of  a  particular
sthma-phenotype  -- i.e.  the  corresponding  endotype(s)  --  is
owadays  crucial  for  its  effective  and  tailored  care.  Neuro-
enic  inﬂammation  may  be  one  these  mechanisms,  as  shown
n  an  experimental  model  of  high  fat  diet-induced  obesity
nd  allergen-challenged  sensitized  mice.8 In  this  model,
etabolic  and  allergic  inﬂammation  parameters  indepen-
ently  increased  Substance-P  (SP)  and  the  presence  of
oth  conditions  further  increased  SP  levels.  In  a  follow-up
tudy,  the  same  group  showed  that  a  SP-antagonist  improved
oth  metabolic  biomarkers  and  the  allergic  inﬂammation,
upporting  this  common  pathway  in  the  obese--asthma  phe-
otype,  and  identifying  SP  as  a  potential  therapeutic  target
n  this  endotype.9
In  this  issue  of  the  journal,  Capelo  et  al.  explore,  in  a
ohort  of  83  asthmatic  women,  the  associations  between
he  abdominal  adiposity  distribution,  asthma  control,  lung
unction  and  cytokines  (adiponectin  and  interleukin-6).10 In
his  cross-sectional  study,  the  authors  addressed  the  associa-
ion  between  subcutaneous  (SAT)  and  visceral  (VAT)  adipose
issues,  measured  by  ultrasound,  and  asthma  control,
ccording  to  Global  Initiative  for  Asthma  (GINA)  criteria.  The
nalyses  were  adjusted  for  important  confounders  such  as
ge,  BMI,  education  level,  rhinitis,  hypertension,  diabetes,
nd  asthma  onset  and  disease  duration.
Their  results  showed  that  women  with  uncontrolled
sthma  have  signiﬁcant  higher  VAT  (cm),  VAT/SAT  ratio  and  aith  controlled  or  partially  controlled  asthma.  Addition-
lly,  a  negative  association  between  VAT  and  VAT/SAT  with
sthma  control  was  found  in  these  women,  after  adjusting
iedade Portuguesa de Pneumologia. This is an open access article
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or  confounders.  Considering  the  association  with  cytokine
evels,  VAT  associated  with  interleukin-6,  while  BMI  and
AT  were  inversely  associated  with  the  ‘‘anti-inﬂammatory’’
diponectin  serum  levels.
The  link  between  obesity  and  asthma  has  been  partially
xplained  by  mechanical  factors,  inﬂammatory  conditions
nd  stress  triggers.11,12 Obesity  causes  a  reduction  in
espiratory  system  compliance,  lung  volumes,  and  periph-
ral  airway  diameter,  as  well  as  an  increase  in  airways
esponsiveness.13 On  the  other  hand,  obesity  is  known  to  be
ssociated  with  chronic  low-grade  systemic  inﬂammation,
ith  an  imbalance  between  pro-  (leptin,  plasminogen  acti-
ator  inhibitor,  IL-6)  and  anti-inﬂammatory  (adiponectin)
ytokines,14 in  line  with  Capelo  et  al.  ﬁndings.  However,
e  have  previously  reported  a  negative  association  between
MI  and  airways  inﬂammation,  measured  by  exhaled  nitric
xide  (FeNO)  in  overweight  and  obese  asthmatics,  provid-
ng  support  to  the  mechanical  hypothesis  linking  obesity  and
sthma.15 Nonetheless,  Capelo  et  al.  hypothesizes  that  it  is
he  visceral  adipose  tissue  (VAT),  and  not  subcutaneous  adi-
osity  or  BMI  that  relates  to  the  pro-inﬂammatory  signals
nd  asthma  control  in  obese  asthmatic  women.  Therefore,
uture  studies  evaluating  the  relation  of  VAT  to  airways
nﬂammation  (e.g.  FeNO)  in  the  obsess-asthma  endotype(s)
re  warranted.
The  cornerstone  for  obesity  treatment  is  a  mul-
icomponent  lifestyle  intervention,  with  lifestyle  or
ehavioural  training,  dietary  change  to  reduce  energy
ntake,  and  an  increase  in  physical  activity  to  increase
nergy  expenditure.16 Likewise,  some  dietary  patterns  seem
o  have  health  beneﬁts.  We  have  previously  described  a
rotective  link  between  a  Mediterranean  diet17 and  n  −  3
olyunsaturated  fatty  acids18 and  asthma  control,  and
etween  a  ‘‘ﬁsh,  vegetables  and  fruit’’  dietary  pattern  and
urrent  persistent  asthma  prevalence,  while  a  detrimental
ssociation  between  a  ‘‘high  fat,  sugar  and  salt’’  dietary
attern  and  severe  asthma  prevalence  was  observed.19
Taken  together,  these  results  reinforce  the  relevance  of
nvestigating  the  relationships  between  asthma  and  obesity,
ndicating  that  body  weight,  waist  circumference  and/or
isceral  adiposity  assessment  should  be  considered  and  inte-
rated  in  day-today  clinical  asthma  care,  and  that  adequate
ody  weight  maintenance  may  also  be  a  preventive  step  to
inimize  the  burden  of  asthma  in  the  global  health  care
ystem.  These  studies  also  provide  rational  for  lifestyle
nterventions  in  the  obesity-asthma  endotype(s),  to  better
nderstand  which  nutritional  intervention,  dietary  modiﬁ-
ation  and  exercise  prescription  will  be  able  to  optimise
ot  only  weight  reduction,  but  also  the  asthma  control  and
atient’s  quality  of  life.
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